CRISPR Therapeutics AG (LTS:0VRQ) Common Stock : $2.70 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Common Stock?

CRISPR Therapeutics AG's quarterly common stock increased from Jun. 2024 ($2.67 Mil) to Sep. 2024 ($2.68 Mil) and increased from Sep. 2024 ($2.68 Mil) to Dec. 2024 ($2.70 Mil).

CRISPR Therapeutics AG's annual common stock increased from Dec. 2022 ($2.44 Mil) to Dec. 2023 ($2.50 Mil) and increased from Dec. 2023 ($2.50 Mil) to Dec. 2024 ($2.70 Mil).

CRISPR Therapeutics AG Common Stock Historical Data

The historical data trend for CRISPR Therapeutics AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Common Stock Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

2.28

2.39

2.44

2.50

2.70

CRISPR Therapeutics AG Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															2.50	2.66	2.67	2.68	2.70

CRISPR Therapeutics AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CRSP:USA CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

CRISPR Therapeutics AG Headlines

No Headlines